Celularity Inc filed 5 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-08-07. Between them they name 3 people, with 4 appointments and 1 departure. Each change below is quoted from the filing and linked to it.
Every change, newest first
Departing: Rick Gonzalez, Chief Commercial Officer
As of such date, Mr. Gonzalez ceased serving as the Company's Chief Commercial Officer.
Reported
Effective June 26, 2026, Vincent LeVien resigned as a member of the Company's Board of Directors.
Appointed: Steven N. Gordon, Chief Operating and Administrative Officer
On June 19, 2026, the Company's Board of Directors (the "Board") appointed Steven N. Gordon, Esq. as the Company's Chief Operating and Administrative Officer.
Appointed: K. Harold Fletcher, Chief Legal and Strategy Officer, effective 2026-06-19
Effective June 19, 2026, the Board also appointed K. Harold Fletcher, Esq. as the Company's Chief Legal and Strategy Officer and Corporate Secretary.
Appointed: Steven N. Gordon, Director, effective 2026-06-19
Effective June 19, 2026, the Board appointed Mr. Gordon as a member of the Board.
Appointed: Rick Gonzalez, Chief Commercial Officer
On May 29, 2026, Celularity Inc. ("Celularity") appointed Rick Gonzalez as Chief Commercial Officer of Celularity.
Reported
On April 15, 2026, Stephen A. Brigido, the Company's President, Degenerative Diseases, resigned from his position, effective immediatly.
Find people with the same kind of experience as the Chief Commercial Officer at Celularity Inc, with the record behind each one.
Find candidates like Chief Commercial Officer at Celularity IncNew leaders review vendors and budgets in their first months. Get an alert the next time Celularity Inc is in the news or changes leadership.
Get an alert when Celularity Inc changes leadershipTools for this story
Each opens in a new tab, filled in for Celularity Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.